Global Vaccine Deals Report 2014-2020: Financial Terms for 1000+ Links to Online Deal Records Entered Into by the World's Leading Healthcare Companies
Dublin, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The "Global Vaccine Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the world's leading healthcare companies.
Trends in vaccine dealmaking in the biopharma industry since 2014
Analysis of vaccine deal structure
Access to headline, upfront, milestone and royalty data
Access to over 1000 vaccine deal documents
The leading vaccine deals by value since 2014
Most active vaccine dealmakers since 2014
The leading vaccine partnering resources
This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 1000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In the report, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Therapy target
Specific technology type
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report provides comprehensive access to available deals and contract documents for over 1000 vaccine deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise vaccine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The report provides the reader with the following key benefits:
In-depth understanding of vaccine and adjuvant deal trends since 2014
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 1000 actual vaccine deals entered into by the world's biopharma companies, together with contract documents if available
Detailed access to actual vaccine contracts enter into by leading bio pharma companies
Identify leading vaccine deals by value since 2014
Identify the most active vaccine dealmakers since 2014
Insight into the terms included in a vaccine agreement
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Companies Mentioned
2A
3D Medicines
3SBio
4D Pharma
A*STAR' Institute of Molecular and Cell Biology
ABEC
ABIVAX
AGC Biologics
Agenus Bio
Agilvax
AIM ImmunoTech
Akers Biosciences
Amyris
Analytical Bio-Chemistry Laboratories
AnGes MG
Anixa Biosciences
Battelle
Batu Biologics
CCT Research
Celldex Therapeutics
Cellular Biomedicine
Celonic
Diavax Biosciences
Diaxonhit
DNA Script
DNAtrix
Dr. Reddy's Laboratories
Frederick National Laboratory For Cancer Research
Fred Hutchinson Cancer Research Center
Fujifilm
GISCAD Foundation
GlaxoSmithKline
Hefei Sageland Biotechnology
Helmholtz Zentrum Munchen
MinervaX
Recipharm
Sanofi
Wyss Institute
Xenetic Biosciences
XstalBio
Y-Biologics
Y-mAbs Therapeutics
Yale University
Yamaguchi University
Yisheng Biopharma
Zenoaq
Zoetis
Zolovax
Zuellig Pharma China
Zydus Cadila
ZYUS Life Sciences
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/e83ugz
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900